MDF strives to help National Institutes of Health (NIH) grant applicants compete for research funding.
Taking as many shots on goal as possible is the only path to approval and reimbursement of safe and effective drugs for DM.
MDF staff recently attended the 2017 annual meeting of the American Academy of Neurology, in Boston, MA. Here are highlights from that meeting.
There have been new discoveries in the way that congenital myotonic dystrophy (CDM) is inherited.
MDF is also happy to help you understand whether something is in a legitimate clinical trial, an approved therapy…or not.